We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · April 05, 2018

Combination Nivolumab and Ipilimumab or Nivolumab Alone in Melanoma Brain Metastases

The Lancet Oncology

 

Additional Info

The Lancet Oncology
Combination Nivolumab and Ipilimumab or Nivolumab Alone in Melanoma Brain Metastases: A Multicentre Randomised Phase 2 Study
Lancet Oncol 2018 Mar 27;[EPub Ahead of Print], GV Long, V Atkinson, S Lo, S Sandhu, AD Guminski, MP Brown, JS Wilmott, J Edwards, M Gonzalez, RA Scolyer, AM Menzies, GA McArthur

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading